Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
Open Access
- 24 February 2023
- journal article
- letter
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 386-388
Abstract
Heejeong Kim, M.D., In-suk Kim, M.D., Ph.D., and Hyerim Kim, M.D., Ph.D.. Ann Lab Med 2023;43:386-8. https://doi.org/10.3343/alm.2023.43.4.386Keywords
Funding Information
- Pusan National University Hospital
This publication has 8 references indexed in Scilit:
- Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemiaExperimental Hematology, 2022
- FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 MutationClinical Cancer Research, 2021
- Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case SeriesFrontiers in Oncology, 2020
- Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid LeukemiaCancer Discovery, 2019
- Targeting FLT3 mutations in AML: review of current knowledge and evidenceLeukemia, 2019
- Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least ResistanceInternational Journal of Molecular Sciences, 2018
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysBlood, 2006